key: cord-0328844-wa8ht8uh authors: Monteil, Vanessa; Stephanie, Devignot; Klingström, Jonas; Thålin, Charlotte; Kellner, Max J.; Christ, Wanda; Havervall, Sebastian; Mereiter, Stefan; Knapp, Sylvia; Montserrat, Nuria; Braunsfeld, Benedict; Kozieradzki, Ivona; Ali, Omar Hasan; Hagelkruys, Astrid; Stadlmann, Johannes; Oostenbrink, Chris; Wirnsberger, Gerald; Penninger, Josef M.; Mirazimi, Ali title: Clinical grade ACE2 effectively inhibits SARS-CoV-2 Omicron infections date: 2021-12-27 journal: bioRxiv DOI: 10.1101/2021.12.25.474113 sha: 489a7324380c6a51968699b1f6b0a4225a671a1c doc_id: 328844 cord_uid: wa8ht8uh The recent emergence of the SARS-CoV-2 variant Omicron has caused considerable concern due to reduced vaccine efficacy and escape from neutralizing antibody therapeutics. Omicron is spreading rapidly around the globe and is suspected to account for most new COVID-19 cases in several countries, though the severity of Omicron-mediated disease is still under debate. It is therefore paramount to identify therapeutic strategies that inhibit the Omicron SARS-CoV-2 variant. Here we report using 3D structural modelling that Spike of Omicron can still associate with human ACE2. Sera collected after the second mRNA-vaccination did not exhibit a protective effect against Omicron while strongly neutralizing infection of VeroE6 cells with the reference Wuhan strain, confirming recent data by other groups on limited vaccine and convalescent sera neutralization efficacy against Omicron. Importantly, clinical grade recombinant human soluble ACE2, a drug candidate currently in clinical development, potently neutralized Omicron infection of VeroE6 cells with markedly enhanced potency when compared to reference SARS-CoV-2 isolates. These data show that SARS-CoV-2 variant Omicron can be readily inhibited by soluble ACE2, providing proof of principle of a viable and effective therapeutic approach against Omicron infections. The initial step of SARS-CoV-2 infection is binding of the viral Spike protein to Angiotensin 54 converting enzyme 2 (ACE2) [1] [2] [3] , followed by proteolytic processing of the trimeric Spike 55 protein [4, 5] . Blocking the Spike/ACE2 interaction is the fundamental principle for the 56 activity of neutralizing antibodies induced by all current vaccines [6, 7] . Similarly, all 57 approved and in development antibodies or nanobodies act by blocking the interaction of 58 the cell-entry receptor ACE2 and the viral Spike protein [8] . Interfering with binding of 59 Spike to its surface receptor ACE2 has become a key paradigm of both vaccine design 60 and multiple therapeutic approaches including ACE2 based therapeutics [9] [10] [11] [12] . Vaccines 61 and antibody therapeutics have had an enormous impact on the COVID-19 pandemic. 62 However, many variants of SARS-CoV-2 have emerged throughout the pandemic [13, 63 14], some of which have been designated variants of concern (VOC) by the WHO 64 because of their increased infectivity and transmissibility. 65 Mutations in the viral Spike protein are of critical importance in viral evolution. These 66 mutations do not only affect the infectivity and transmissibility of SARS-CoV-2, but also 67 reduce the potency of vaccines, convalescent sera, and monoclonal antibody 68 therapeutics [14] [15] [16] [17] [18] [19] [20] . The recent emergence of the Omicron variant, which contains 61 69 nonsynonymous mutations relative to the original Wuhan strain, is a key example [21] [22] [23] 70 More such variants will probably evolve in the future, also in part due to population scale 71 measurements and thereby mounting evolutionary pressure on the virus strains. Importantly, structural modelling of ACE2 binding revealed that pre-fusion Omicron Spike 115 could still associate with human ACE2 (Figure 1c ). Mutations Omicron will infect rodents. We also modelled the 22 N-glycosylation sites of Spike we 124 and others have previously reported, some of which (N165, N234, N343) directly interact 125 with ACE2 or its glycans [36, 37] . Intriguingly, despite the unprecedented number of 126 observed mutations, none of the N-glycosylation sites critical for ACE2 binding are altered 127 in Omicron Spike (Figure 1c ). These molecular modelling data support that pre-fusion 128 Omicron Spike can still readily associate with human ACE2. 129 Impaired neutralization of Omicron by RNA vaccine elicited antibodies. 130 We finally tested whether sera from vaccinated people could also still neutralize Omicron 131 infections of VeroE6 cells. To this end, we obtained sera from four SARS-CoV-2 naïve 132 healthcare workers who received an mRNA vaccine (Comirnaty); these sera were 133 collected following ethic approvals 5-7 weeks after the second vaccination. In all cases 134 we observed significant inhibition of infection of the reference SARS-CoV-2 strain. However, at the dilutions used we did not detect any neutralization of Omicron infection We length Spike proteins of all tested variants (alpha, beta, gamma, delta), but also more 146 potently inhibits viral infection by these strains [30, 31] . To test whether APN01 can also neutralize Omicron SARS-CoV-2 isolates, we performed 148 neutralization assays in VeroE6 cells and compared its inhibitory potency side by side to tested in phase 1 trials to assess its safety and tolerability. The source of the VOC Omicron is currently unclear and multiple hypotheses have been Structural basis of receptor recognition by SARS-CoV-2 A pneumonia outbreak associated with a new coronavirus of 358 probable bat origin Structural and Functional Basis of SARS-CoV-2 Entry by Using 360 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 SARS-CoV-2 variants, spike mutations and immune escape Reduced sensitivity of SARS-CoV-2 variant Delta to antibody 386 neutralization Multiple SARS-CoV-2 variants escape neutralization 388 by vaccine-induced humoral immunity Escape of SARS-CoV-2 501Y.V2 from neutralization by 390 convalescent plasma Mapping mutations to the SARS-CoV-2 RBD that escape 392 binding by different classes of antibodies Effectiveness of Covid-19 Vaccines against the B.1.617.2 395 (Delta) Variant SARS-CoV-2 spike E484K mutation reduces antibody 397 neutralisation. The Lancet Microbe Transmission event of SARS-CoV-2 Delta variant reveals 399 multiple vaccine breakthrough infections. medRxiv Delta Variants of SARS-CoV-2 Cause Significantly 402 Increased Vaccine Breakthrough COVID-19 Cases in Early assessment of the clinical severity of the SARS-CoV-2 South Africa. medRxiv Population impact of SARS-CoV-2 variants with enhanced 407 transmissibility and/or partial immune escape High Fidelity of Murine Hepatitis Virus Replication Is 410 Decreased in nsp14 Exoribonuclease Mutants Infidelity of SARS-CoV Nsp14-Exonuclease Mutant Virus 413 Replication Is Revealed by Complete Genome Sequencing Mechanism of molnupiravir-induced SARS-CoV-2 Reduced Neutralization of SARS-CoV-2 Omicron Variant by 418 Plasma neutralization properties of the SARS-CoV-2 Omicron 421 variant. medRxiv SARS-CoV-2 Omicron strain exhibits potent capabilities for 423 immune evasion and viral entrance Clinical grade ACE2 as a universal agent to block SARS-426 CoV-2 variants Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine 428 efficacy A mouse-adapted model of SARS-CoV-2 to test COVID-430 19 countermeasures Q493K and Q498H substitutions in Spike promote adaptation of 52 A diabetic milieu increases cellular 474 susceptibility to SARS-CoV-2 infections in engineered human kidney organoids 475 and diabetic patients. bioRxiv A CRISPR/Cas9 genetically engineered organoid biobank 477 reveals essential host factors for coronaviruses Antihypertensive drug treatment and susceptibility to SARS-480 CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial 481 cells Trilogy of ACE2: A peptidase in the renin-angiotensin system, a 483 SARS receptor, and a partner for amino acid transporters Angiotensin-Converting Enzyme 2 486 (ACE2) in the Pathogenesis of ARDS in COVID-19 SARS-CoV-2-induced lung injury Development of a novel, pan-variant aerosol 491 intervention for COVID-19